H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Taro Pharma (NYSE: TARO) today and set a price target of $120. The company’s shares closed yesterday at $112.74.
Selvaraju observed:
“Valuation methodology, risks and uncertainties. We ascribe a price objective of $120 per share, based on a forward EPS multiple of 15.7x applied to our current fiscal 2019 EPS forecast of $7.65 per share.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -1.7% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Taro Pharma is a Moderate Buy with an average price target of $120.
See today’s analyst top recommended stocks >>
The company has a one-year high of $128.46 and a one-year low of $93.01. Currently, Taro Pharma has an average volume of 52.47K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
